Dachsie comment: Was researching Dr. Paul E. Alexander's publised scientific papers. Found this one. I think this is a "Pre-Print" which means this is not peer reviewed.
I heard that this experimental anti- viral medicine, remdesivir, has now been found to be associated with a 20 percent rate of RENAL failure!

___________________________________

...https://www.researchgate.net/publica..._meta-analysis...

HomePublic HealthCOVID-19

PreprintPDF Available
Remdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysis

May 2020

DOI:10.1101/2020.05.23.20110932
Authors:
Paul Elias Alexander
Joshua Piticaru
Kim Lewis

McMaster University

Komal Aryal

McMaster University

Priya Thomas

McMaster University

Wojciech Szczeklik

Jagiellonian University

Jakub Fronczek

Jagiellonian University

Kamil Polok

Jagiellonian University

Waleed Alhazzani

McMaster University

Manoj Mammen

University at Buffalo, The State University of New York

Abstract and Figures
Background Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus SARS-CoV-2, has led to significant global mortality and morbidity. Until now, no treatment has proven to be effective in COVID-19. To explore whether the use of remdesivir, initially an experimental broad-spectrum antiviral, is effective in the treatment of hospitalized patients with COVID-19, we conducted a systematic review and meta-analysis of randomized, placebo-controlled trials investigating its use. Methods A rapid search of the MEDLINE and EMBASE medical databases was conducted for randomized controlled trials. A systematic approach was used to screen, abstract, and critically appraise the studies. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) method was applied to rate the certainty and quality of the evidence reported per study. Results Two RCTs studies were identified (n=1,299). A fixed-effects meta-analysis revealed reductions in mortality (RR=0.69, 0.49 to 0.99), time to clinical improvement (3.95 less days, from 3.86 days less to 4.05 less days ), serious adverse events (RR=0.77, 0.63 to 0.94) and all adverse events (RR=0.87, 0.79 to 0.96). Conclusion In this rapid systematic review, we present pooled evidence from the 2 included RCT studies that reveal that remdesivir has a modest yet significant reduction in mortality and significantly improves the time to recovery, as well as significantly reduced risk in adverse events and serious adverse events. It is more than likely that as an antiviral, remdesivir is not sufficient on its own and may be suitable in combination with other antivirals or treatments such as convalescent plasma. Research is ongoing to clarify and contextual these promising findings.
Mortality using remdesivir in hospitalized patients with COVID-19
Mortality using remdesivir in hospitalized patients with COVID-19
…
GRADE evidence table
GRADE evidence table
…